Breast Cancer Trial, Recruiting (NCT05057598)

Breast Cancer Trial, Recruiting NCT05057598 Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05057598 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women who have been diagnosed with breast cancer
Women whose breast cancer has come back (relapsed) after previous treatment
Women whose breast cancer has spread to other parts of the body (metastases)
Women who were diagnosed with breast cancer in the past, even if it was many years ago
Women who have been diagnosed with breast cancer and also have another type of cancer
Women who have been diagnosed with breast cancer and also have another health condition that affects their thinking, memory, or mental abilities

Who may not be able to join:

Women with breast cancer who have also been diagnosed with Alzheimer's Disease
Women with breast cancer who have also been diagnosed with dementia
Women with breast cancer who are unable to use a personal computer or smartphone

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 5 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: ANNA VILLARINI, PhD, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Phone: +390223903552

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05057598

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

Trial contact: +390223903552

More information: https://clinicaltrials.gov/study/NCT05057598

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women who have been diagnosed with breast cancer
Women whose breast cancer has come back (relapsed) after previous treatment
Women whose breast cancer has spread to other parts of the body (metastases)
Women who were diagnosed with breast cancer in the past, even if it was many years ago
Women who have been diagnosed with breast cancer and also have another type of cancer
Women who have been diagnosed with breast cancer and also have another health condition that affects their thinking, memory, or mental abilities

Who may not be able to join:

Women with breast cancer who have also been diagnosed with Alzheimer's Disease
Women with breast cancer who have also been diagnosed with dementia
Women with breast cancer who are unable to use a personal computer or smartphone

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 5 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Registry

ClinicalTrials.gov

Start date

21 June 2016

Est. completion

31 December 2023

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Increase rate of survival; Decrease incidence of relapses; Decrease incidence of metastasis; Decrease incidence of Metabolic Syndrome parameters; Decrease blood level on C-reactive protein (chronic inflammation marker); Decrease the insulin resistance index (HOMA index)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov